Quadria Capital https://validator.w3.org/feed/docs/rss2.html About Quadria Capital Secures Partial Exit in NephroPlus IPO Amid Strong Investor Demand Quadria Capital and Co-investors Complete Landmark Take-Private of Apex Healthcare Apex Healthcare Quadria Capital Selected for ImpactAssets 50 2026 Annual General Meeting 2025 BlueMark Fund ID Verifier Statement 2025 Quadria Achieves Top UN PRI Ratings in Inaugural Year Quadria Capital Awarded Fundraise of the Year 2025 by Singapore Venture & Private Capital Association Privacy Policy Quadria Impact Strategy 2024 Quadria Responsible Investing Policy Statement 2024 Quadria Capital OPIM Disclosure Statement 2024 Financing The Climate – Health Frontier Emering Opportunities Contact Quadria Capital Climate Action For Health Report 2024 Impact and ESG Straits Orthopaedics Expands Global Footprint with Acquisition of U.S.-Based Medin Technologies, Strengthening Orthopaedic Manufacturing Portfolio Quadria Capital Closes Oversubscribed US$1 Billion Fund III to Advance Healthcare Transformation Across Asia Aragen Life Sciences Quadria Annual Review 2025-26 Quadria Investing for Impact Report 2024 NephroPlus Concord Biotech (2023) Royal Healthcare (2025) AIG Maxivision Portfolio Approach Quadria Annual Review 2024-25 Quadria Capital wins Singapore Venture & Private Capital Association’s Private Equity Deal of the Year for the second year in a row Quadria Capital partially exits Akums Drugs and Pharmaceuticals through IPO FV Hospital Hermina FV Hospital (2023) NephroPlus Case Study Investing for Impact 404 Terms Publications Careers Aragen secures $100 Mn investment from Quadria Capital Hermina Case Study Akums Drugs and Pharmaceuticals (Partial Exit 2024) Lablink (2021) Strand Life Sciences (2021) Asian Institute of Gastroenterology (2022) SOHO Global Health (2020) Medica Superspeciality Hospital (2021) Home